PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Montréal-based biotech company KisoJi Biotechnology has raised $57 million CAD ($41 million USD) to bring its cancer treatment into clinical trials and leverage artificial intelligence (AI) for its ...